Frontal Fibrosing Alopecia Clinical Trial
Official title:
Assessment of the Safety and Efficacy of Intralesional Platelet Rich Plasma in Reducing Scalp Symptoms and Promoting Hair Growth in Frontal Fibrosing Alopecia
The primary objective of this study is to assess the efficacy and safety of platelet rich plasma in reducing scalp symptoms and promoting hair growth in patients diagnosed with frontal fibrosing alopecia. Platelet rich plasma is an autologous blood product, and platelet rich plasma will be administered intralesionally for this study. The platelet rich plasma used for this study will be prepared using the Eclipse Easy Spin centrifuge.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | September 2026 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males and females, ages 18 and older - Diagnosed by a board-certified dermatologist with frontal fibrosing alopecia - Scalp biopsy consistent with frontal fibrosing alopecia diagnosis - Willing to use Head and Shoulders shampoo for the scalp while in study - Willing to abstain from over the counter and prescription hair/scalp products other than those supplied in the study - Willing to abstain from the use of non-steroidal anti-inflammatory medications, aspirin, St, John's Wart, and high doses of Vitamin E supplementation for 4 weeks - Subjects must be capable of giving informed consent - Stated willingness to comply with all study procedures and be available for the duration of the study - For women with reproductive potential, a willingness to use methods of contraception that will prevent the subject from becoming pregnant during the study. Adequate contraception methods include hormonal methods used for two or more menstrual cycles before screening (eg. oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), barrier methods (eg, contraceptive sponge, diaphragm in conjunction with contraceptive foam or jelly, or condom in conjunction with contraceptive foam or jelly), intrauterine methods (IUD), sterilization (eg, tubal ligation or a monogamous relationship with a vasectomized partner) and abstinence Exclusion Criteria: - Current immunosuppression - Oral treatment of FFA within the last 3 months (such as hydroxycholroquine, doxycycline, minocycline, acitretin, mycophenolate mofetil, cyclosporine, prednisone, rituximab, and pioglitazone etc.) - History of other scalp/hair disease - Current chemotherapy or radiation - Propensity for keloids or hypertrophic scarring - Autoimmune disorders - Hematologic disorder or bleeding disorder - Platelet dysfunction - Use of anticoagulation therapy - Active malignancy - Use of intralesional or topical corticosteroids in the last 6 weeks - Scalp atrophy - Pregnant and/or breastfeeding - Allergy or intolerance to triamcinolone - Severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies - Medical problems including HIV, connective tissue disorder, PCOS, or untreated thyroid disease - Any psychiatric or medical condition that in the opinion of the investigator will interfere with patient's ability to participate in the trial - Current use of tanning beds or any active tanning - Planned upcoming pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota Department of Dermatology | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in the LPPAI score from baseline | Changes in LPPAI (LICHEN PLANOPILARIS ACTIVITY INDEX) Scale of of 0-4 0= None 4=Severe | Baseline to 3 years | |
Primary | Changes in the hair growth from baseline to the completion of the study • Change in hair growth from baseline to study completion via investigator assessment of scalp photography | Changes in hair growth from baseline to study completion using scalp photography hair growth in patients diagnosed with frontal fibrosing alopecia | Baseline to 3 years | |
Secondary | self-assessment using the Dermatology Quality Life Index | Subject self-assessment using the Dermatology Quality Life Index (DQLI) | Baseline to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04409041 -
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
|
Phase 2 | |
Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
Enrolling by invitation |
NCT06202560 -
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
|
N/A | |
Not yet recruiting |
NCT02467101 -
Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia
|
N/A | |
Recruiting |
NCT03422640 -
Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia
|
Phase 4 | |
Completed |
NCT03346668 -
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
|
Early Phase 1 | |
Active, not recruiting |
NCT03082560 -
Design and Validation of a New Assessment Tool for Lichen Planopilaris
|
||
Completed |
NCT04342091 -
Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
|
N/A | |
Recruiting |
NCT06240351 -
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
|
Phase 4 | |
Completed |
NCT05332366 -
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
|
Phase 2 |